Lion Biotechnologies Inc. (LBIO) Reaches New 52-Week High at $9.45
Shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $9.45 and last traded at $8.93, with a volume of 439,439 shares. The stock had previously closed at $8.84.
Several analysts recently weighed in on LBIO shares. Roth Capital restated a “buy” rating and set a $15.00 target price on shares of Lion Biotechnologies in a research note on Saturday, July 9th. Zacks Investment Research upgraded Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a research report on Tuesday, June 14th. FBR & Co reiterated a “buy” rating on shares of Lion Biotechnologies in a research report on Monday, June 6th. SunTrust Banks Inc. downgraded Lion Biotechnologies from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $37.00 to $30.50 in a research report on Monday, June 6th. Finally, Chardan Capital reiterated a “buy” rating on shares of Lion Biotechnologies in a research report on Saturday, June 4th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Lion Biotechnologies presently has a consensus rating of “Buy” and an average price target of $19.17.
The stock has a 50-day moving average price of $8.10 and a 200 day moving average price of $6.20. The company’s market capitalization is $435.51 million.
Lion Biotechnologies (NASDAQ:LBIO) last released its earnings results on Monday, May 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. Equities analysts predict that Lion Biotechnologies Inc. will post ($0.73) earnings per share for the current year.
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.